
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. has demonstrated a positive financial trajectory, with its third-quarter revenue surpassing consensus expectations and management increasing the guidance midpoint, indicating robust business growth. The company has also revised its gross margin guidance upward to 76-77%, reflecting improved efficiencies and a favorable product mix, particularly from higher-margin light adjustable lenses (LALs). Additionally, strategic initiatives aimed at enhancing engagement and driving volume growth for LDD placements are expected to contribute to further improvements in both revenue and margins, positioning RxSight positively within the medical technology sector.
Bears say
RxSight Inc. has experienced a decline in LAL (Light Adjustable Lens) utilization, with monthly usage falling to 8.0 LALs per LDD in 3Q25, down from 8.7 in 2Q25 and 10.1 in 3Q24, indicating potential challenges in customer adoption or market penetration. The company's revenue for 3Q25 was reported at $30.3 million, reflecting a year-over-year decrease of 14%, and management has projected FY2026 revenue to be between $120 million and $135 million, which is below prior estimates and indicates a potential contraction of 11% year-over-year. Furthermore, RxSight anticipates that gross margins will face pressure from higher-cost inventory starting in 2Q26, signaling further financial strain as the company grapples with both declining revenues and increasing operational costs.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares